of New York is a publicly traded (Nasdaq: ORTC) company that has developed and patented a product called Composite Cultured Skin
, which is used to stimulate the repair and regeneration of human skin, particularly in burn victims.
Composite cultured skin
(CCS) is composed of human skin cells, which are derived from infant foreskin and placed on a porous collagen scaffold.
The company calls the product "composite cultured skin
" and plans to market it as OrCel.
Ortec's current focus is the application of its Composite Cultured Skin
(CCS) product to heal chronic and acute wounds.